Smithers, a bioanalytical contract research organization (CRO), has developed and validated over 100 PK and ADA assays for therapeutic monoclonal and polyclonal antibodies. Smithers also currently supports many cell-based neutralizing antibody assays in phase III clinical trials, supporting monoclonal/polyclonal antibody development from discovery through phase IV.
Show Policy

Latest Resources

See all resources